This clinical scenario involves treatment-naive patients with environmental metaplastic atrophic gastritis (EMAG) who have active Helicobacter pylori infection confirmed by a nonserological test and a documented true penicillin allergy — a constraint that significantly narrows the eligible first-line eradication options.
Among the recommended and guideline-supported first-line options for treatment-naive patients, only an optimized bismuth-based quadruple eradication regimen is appropriate for patients with a true penicillin allergy.
Full regimen composition, component selection criteria, dosing guidance, and monitoring requirements are detailed in the structured protocol.
Confirmed eradication of H. pylori, verified by a test of cure — urea breath test, fecal antigen test, or biopsy-based test — conducted at least 4 weeks after completion of therapy.
DOI: 10.14309/ajg.0000000000002968
We summarize treatment recommendations for patients with active H. pylori infection, as confirmed by a nonserological test, who have not been previously treated (i.e., "treatment-naive" patients) and those with persistent infection despite previous attempt(s) at eradication (i.e., "treatment-experienced" patients).
Of the recommended and suggested options for treatment-naive patients, only optimized BQT is suitable for patients with a true penicillin allergy.
In treatment-naive patients with H. pylori infection, optimized BQT is recommended as a first-line treatment option (strong recommendation; moderate quality evidence).
All patients who are treated for H. pylori infection should undergo a test of cure with an appropriately conducted urea breath test, fecal antigen test, or biopsy-based test at least 4 weeks after completion of therapy.
View source ↗